Per Kallblad
Tracked across 1 events · 6 articles · First seen Sep 22, 2026 · Last active Sep 22, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Bicara Therapeutics AB, a privately held Swedish precision medicine company, announced on September 22, 2026 the initiation of IND-enabling studies for BEA-17, its wholly owned, first-in-class oral degrader of the epigenetic regulators LSD1 and CoREST,…
Impact: As Chief Executive Officer of Bicara Therapeutics, Per Kallblad publicly framed the IND-enabling studies as a defining milestone for the BEA-17 programme. His role is communicative and leadership-oriented rather than directly market-moving.
Sep 22, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Per Kallblad live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard